非酒精性脂肪性肝炎相关显著纤维化和肝硬化中低肝脏脂肪与肝细胞癌、失代偿和死亡率相关
本项个体参与者数据的Meta分析纳入456例同时接受磁共振弹性成像(MRE)和MRI衍生质子密度脂肪分数(MRI-PDFF)检测的患者,其中296例有纵向随访。结果显示,在NASH相关显著纤维化和肝硬化患者中,低肝脏脂肪含量与肝失代偿、肝细胞癌(HCC)和死亡风险升高相关(HR=42.2,95%CI:7.5-235.5,p<0.0001)。
要点
- 在NASH相关显著纤维化患者中,低肝脏脂肪含量组(MRI-PDFF<5%)的失代偿、HCC和死亡率分别为33%、17%和17%。
- 较高肝脏脂肪含量组(MRI-PDFF≥5%)的失代偿、HCC和死亡率分别为18%、13%和13%。
- 无显著纤维化组(MEFIB阴性)的失代偿、HCC和死亡率分别为0%、1%和2%。
核心结论
- 在NASH相关显著纤维化和肝硬化患者中,低肝脏脂肪含量与肝失代偿、HCC和死亡率增加相关。
研究设计与样本
- 本项个体参与者数据的Meta分析纳入456例同时接受MRE和MRI-PDFF检测的患者,其中296例有纵向随访。
- 根据MEFIB指数和MRI-PDFF将患者分为无显著纤维化组、NASH伴显著纤维化且较高肝脏脂肪含量组(MRI-PDFF≥5%)和NASH伴显著纤维化且低肝脏脂肪含量组(MRI-PDFF<5%)。
- 主要结局为肝失代偿、HCC和死亡。
主要发现
- 失代偿、HCC和死亡率在NASH伴显著纤维化且低肝脏脂肪组最高(分别为33%、17%和17%),其次为NASH伴显著纤维化且较高肝脏脂肪组(分别为18%、13%和13%),无显著纤维化组最低(分别为0%、1%和2%)。
- 多变量校正分析中,低肝脏脂肪含量与HCC、失代偿和死亡强烈相关(HR=42.2,95%CI:7.5-235.5,p<0.0001)。
- 针对肝硬化患者(MRE≥5 kPa)的敏感性分析结果一致。
关键数值与推荐
- MEFIB阴性定义为无显著肝纤维化;MEFIB阳性且MRI-PDFF≥5%定义为NASH伴显著纤维化且较高肝脏脂肪含量;MEFIB阳性且MRI-PDFF<5%定义为NASH伴显著纤维化且低肝脏脂肪含量。
- 肝硬化敏感性分析定义MRE≥5 kPa。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progression to cirrhosis in non-alcoholic steatohepatitis (NASH) is associated with a decrease in liver fat. However, the prognostic significance of liver fat content in NASH-related significant fibrosis and cirrhosis is unclear. AIM: To investigate the risk of decompensation, hepatocellular carcinoma (HCC) and mortality stratified by liver fat content in NASH-related significant fibrosis and cirrhosis. METHODS: In this meta-analysis of individual participant data, 456 patients with both magnetic resonance elastography (MRE) and MRI-derived protein density fat fraction (MRI-PDFF) were enrolled, and 296 patients with longitudinal follow-up were analysed. MRE combined with fibrosis-4 (MEFIB-index), and MRI-PDFF were used to measure liver fibrosis and fat, respectively. MEFIB-negative, MEFIB-positive+ MRI-PDFF ≥5% and MEFIB-positive+ MRI-PDFF <5% were defined as no significant liver fibrosis, NASH with significant fibrosis and higher liver fat content, and NASH with significant fibrosis and low liver fat content groups, respectively. The primary outcome was hepatic decompensation, HCC and death. RESULTS: The rates of decompensation, HCC and mortality were highest in the NASH with significant fibrosis and low liver fat group (33%, 17% and 17%, respectively), followed by the NASH with significant fibrosis and higher liver fat group (18%, 13% and 13% respectively), and lowest in the no significant fibrosis (MEFIB-negative) group (0%, 1% and 2% respectively). In multivariable-adjusted analysis, low liver fat content was strongly associated (HR = 42.2 [95% CI: 7.5-235.5, p < 0.0001]) with HCC, decompensation and death. Sensitivity analyses for patients with cirrhosis (MRE ≥5 kPa) determined consistent findings. CONCLUSIONS: Low liver fat content in patients with burnt-out NASH-related significant fibrosis and cirrhosis is associated with an increase in hepatic decompensation, HCC and mortality.
引用
- Lee SW, Huang DQ, Bettencourt R, et al. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality. Aliment Pharmacol Ther. 2023. PMID: 37968251. doi:10.1111/apt.17783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。